Cargando…

Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial

The multimodal activities of farnesoid X receptor (FXR) agonists make this class an attractive option to treat nonalcoholic steatohepatitis. The safety and efficacy of tropifexor, an FXR agonist, in a randomized, multicenter, double-blind, three-part adaptive design, phase 2 study, in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sanyal, Arun J., Lopez, Patricia, Lawitz, Eric J., Lucas, Kathryn J., Loeffler, Juergen, Kim, Won, Goh, George B. B., Huang, Jee-Fu, Serra, Carla, Andreone, Pietro, Chen, Yi-Cheng, Hsia, Stanley H., Ratziu, Vlad, Aizenberg, Diego, Tobita, Hiroshi, Sheikh, Aasim M., Vierling, John M., Kim, Yoon Jun, Hyogo, Hideyuki, Tai, Dean, Goodman, Zachary, Schaefer, Felicity, Carbarns, Ian R. I., Lamle, Sophie, Martic, Miljen, Naoumov, Nikolai V., Brass, Clifford A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941046/ https://www.ncbi.nlm.nih.gov/pubmed/36797481 http://dx.doi.org/10.1038/s41591-022-02200-8

Ejemplares similares

Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study
por: Anstee, Quentin M., et al.
Publicado: (2023)

Tropifexor‐Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents
por: Hernandez, Eloy D., et al.
Publicado: (2019)

A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitis
por: Newsome, Philip N., et al.
Publicado: (2023)

Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved
por: Yoneda, Masato, et al.
Publicado: (2023)

The scaffold-dependent function of RIPK1 in experimental non-alcoholic steatohepatitis
por: Pistorio, Valeria, et al.
Publicado: (2022)

Determination of Tropifexor in Beagle Dog Plasma by UPLC-MS/MS and Its Application in Pharmacokinetics
por: Su, Yan-Ding, et al.
Publicado: (2022)

The effect of Farnesoid X receptor agonist tropifexor on liver damage in rats with experimental obstructive jaundice
por: Kilavuz, Huseyin, et al.
Publicado: (2021)

Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis
por: Schramm, Christoph, et al.
Publicado: (2022)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non–Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers
por: Badman, Michael K., et al.
Publicado: (2019)

Treatment of Nonalcoholic Steatohepatitis in Adults: Present and Future
por: Gitto, S., et al.
Publicado: (2015)

Validation of NASH-CHECK: a novel patient-reported outcome measure for nonalcoholic steatohepatitis
por: Twiss, James, et al.
Publicado: (2023)

Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science
por: Siddiqui, Mohammad Shadab, et al.
Publicado: (2018)

Recent advances in understanding/management of non-alcoholic steatohepatitis
por: Pacana, Tommy, et al.
Publicado: (2015)

Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis
por: Albhaisi, Somaya, et al.
Publicado: (2021)

Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study
por: Doward, Lynda C., et al.
Publicado: (2020)

Drug discovery and treatment paradigms in nonalcoholic steatohepatitis
por: Noureddin, Mazen, et al.
Publicado: (2019)

Lithium Monitoring Within NHS Forth Valley 2020
por: Carbarns, Amy
Publicado: (2022)

Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis
por: Sanyal, Arun J., et al.
Publicado: (2022)

A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
por: Friedman, Scott L., et al.
Publicado: (2018)

Bach1 gene ablation reduces steatohepatitis in mouse MCD diet model
por: Inoue, Motoki, et al.
Publicado: (2011)

Harnessing Muscle–Liver Crosstalk to Treat Nonalcoholic Steatohepatitis
por: Chakravarthy, Manu V., et al.
Publicado: (2020)

Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study
por: O'Hara, Jamie, et al.
Publicado: (2020)

Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis
por: Angelis, Aris, et al.
Publicado: (2020)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Fibrosis-4 index is associated with the risk of hepatocellular carcinoma in patients with cirrhosis and nonalcoholic steatohepatitis
por: Albhaisi, Somaya, et al.
Publicado: (2023)

Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
por: Sumida, Yoshio, et al.
Publicado: (2020)

Short review on the diagnosis and treatment of bronchiectasis
por: Lesan, Andrei, et al.
Publicado: (2019)

Metabolomic Profiling to Identify Predictors of Response to Vitamin E for Non-Alcoholic Steatohepatitis (NASH)
por: Cheng, Jianfeng, et al.
Publicado: (2012)

Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient‐Reported Outcomes
por: Younossi, Zobair M, et al.
Publicado: (2020)

Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients
por: Lawitz, Eric J., et al.
Publicado: (2022)

Review article: the impact of liver‐directed therapies on the atherogenic risk profile in non‐alcoholic steatohepatitis
por: Connelly, Margery A., et al.
Publicado: (2020)

Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
por: Newsome, Philip, et al.
Publicado: (2019)

An Evaluation of the Collagen Fragments Related to Fibrogenesis and Fibrolysis in Nonalcoholic Steatohepatitis
por: Luo, Yi, et al.
Publicado: (2018)

FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trial
por: Wai-Sun Wong, Vincent, et al.
Publicado: (2023)

Apoptosis and diagnosis of nonalcoholic steatohepatitis
por: Kim, Chang Wook, et al.
Publicado: (2011)

Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway
por: Filozof, Claudia, et al.
Publicado: (2015)

Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis
por: Alkhouri, Naim, et al.
Publicado: (2018)

Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study
por: Tobita, Hiroshi, et al.
Publicado: (2017)

Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis
por: Sanyal, Arun J., et al.
Publicado: (2023)

Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis
por: Luo, Yi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_979f275hslmvbct38clc03teou